Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302

Reuters12-17 21:10

Dec 17 (Reuters) - Soligenix Inc ::
*SOLIGENIX ANNOUNCES TOP-LINE RESULTS OF THE PHASE 2A STUDY OF SGX302 (SYNTHETIC HYPERICIN) IN PATIENTS WITH MILD-TO-MODERATE PSORIASIS
*SOLIGENIX INC - OPTIMIZED GEL FORMULATION SHOWS SUCCESS IN THIRD COHORT
*SOLIGENIX INC - SGX302 GEL THERAPY WELL TOLERATED WITH NO ADVERSE EVENTS
*SOLIGENIX INC - STUDY CONFIRMS SGX302 IMPROVES PSORIASIS LESIONS

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 17-DEC-202512:30:00.08 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592296990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592296990","market":"fut","top_or_hot":-1,"title":"Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302","media":"Reuters","content":"<html><body>Dec 17 (Reuters) - Soligenix Inc <sngx.o>::<br/>*SOLIGENIX ANNOUNCES TOP-LINE RESULTS OF THE PHASE 2A STUDY OF SGX302 (SYNTHETIC HYPERICIN) IN PATIENTS WITH MILD-TO-MODERATE PSORIASIS<br/>*SOLIGENIX INC - OPTIMIZED GEL FORMULATION SHOWS SUCCESS IN THIRD <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a><br/>*SOLIGENIX INC - SGX302 GEL THERAPY WELL TOLERATED WITH NO ADVERSE EVENTS<br/>*SOLIGENIX INC - STUDY CONFIRMS SGX302 IMPROVES PSORIASIS LESIONS<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 17-DEC-202512:30:00.08 GMT</sngx.o></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Dec 17 (Reuters) - Soligenix Inc <sngx.o>::<br/>*SOLIGENIX ANNOUNCES TOP-LINE RESULTS OF THE PHASE 2A STUDY OF SGX302 (SYNTHETIC HYPERICIN) IN PATIENTS WITH MILD-TO-MODERATE PSORIASIS<br/>*SOLIGENIX INC - OPTIMIZED GEL FORMULATION SHOWS SUCCESS IN THIRD <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a><br/>*SOLIGENIX INC - SGX302 GEL THERAPY WELL TOLERATED WITH NO ADVERSE EVENTS<br/>*SOLIGENIX INC - STUDY CONFIRMS SGX302 IMPROVES PSORIASIS LESIONS<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 17-DEC-202512:30:00.08 GMT</sngx.o></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNGX","symbol_name":"Soligenix, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nRSD4Mqw9S:1","article_id":"2592296990","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592296990","pubTimestamp":1765977028,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dec 17 (Reuters) - Soligenix Inc ::*SOLIGENIX ANNOUNCES TOP-LINE RESULTS OF THE PHASE 2A STUDY OF SGX302 (SYNTHETIC HYPERICIN) IN PATIENTS WITH MILD-TO-MODERATE PSORIASIS*SOLIGENIX INC - OPTIMIZED GEL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNGX":"Soligenix, Inc.","BK4139":"生物科技"},"translate_title":"Soligenix公布SGX302 2a期研究的顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNGX":0.9},"content_text":"Dec 17 (Reuters) - Soligenix Inc ::*SOLIGENIX ANNOUNCES TOP-LINE RESULTS OF THE PHASE 2A STUDY OF SGX302 (SYNTHETIC HYPERICIN) IN PATIENTS WITH MILD-TO-MODERATE PSORIASIS*SOLIGENIX INC - OPTIMIZED GEL FORMULATION SHOWS SUCCESS IN THIRD COHORT*SOLIGENIX INC - SGX302 GEL THERAPY WELL TOLERATED WITH NO ADVERSE EVENTS*SOLIGENIX INC - STUDY CONFIRMS SGX302 IMPROVES PSORIASIS LESIONS  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 17-DEC-202512:30:00.08 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592296990","isCrawlerRequest":true}